Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
1.590
-0.050 (-3.05%)
Feb 11, 2026, 2:12 PM EST - Market open
Ovid Therapeutics Employees
Ovid Therapeutics had 23 employees as of December 31, 2024. The number of employees decreased by 17 or -42.50% compared to the previous year.
Employees
23
Change
-17
Growth
-42.50%
Revenue / Employee
$287,391
Profits / Employee
-$1,559,652
Market Cap
206.99M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 23 | -17 | -42.50% |
| Sep 30, 2024 | 25 | -14 | -35.90% |
| Jun 30, 2024 | 40 | 0 | - |
| Mar 31, 2024 | 40 | -6 | -13.04% |
| Dec 31, 2023 | 40 | -4 | -9.09% |
| Sep 30, 2023 | 39 | -5 | -11.36% |
| Jun 30, 2023 | 40 | -4 | -9.09% |
| Mar 31, 2023 | 46 | -3 | -6.12% |
| Dec 31, 2022 | 44 | -13 | -22.81% |
| Sep 30, 2022 | 44 | -1 | -2.22% |
| Jun 30, 2022 | 44 | -16 | -26.67% |
| Mar 31, 2022 | 49 | -15 | -23.44% |
| Dec 31, 2021 | 57 | -10 | -14.93% |
| Sep 30, 2021 | 45 | -20 | -30.77% |
| Jun 30, 2021 | 60 | 0 | - |
| Mar 31, 2021 | 64 | -1 | -1.54% |
| Dec 31, 2020 | 67 | 8 | 13.56% |
| Sep 30, 2020 | 65 | 11 | 20.37% |
| Jun 30, 2020 | 60 | 13 | 27.66% |
| Mar 31, 2020 | 65 | 12 | 22.64% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Protalix BioTherapeutics | 213 |
| Arcturus Therapeutics Holdings | 176 |
| Voyager Therapeutics | 172 |
| Alector | 156 |
| Silence Therapeutics | 116 |
| Tonix Pharmaceuticals Holding | 81 |
| Inhibikase Therapeutics | 16 |
| Nuvectis Pharma | 13 |
OVID News
- 15 days ago - Ovid Therapeutics: Bullish Post-PIPE With 2 Differentiated CNS Moonshots - Seeking Alpha
- 7 weeks ago - Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) - GlobeNewsWire
- 2 months ago - Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer - GlobeNewsWire
- 3 months ago - Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Ovid Therapeutics Inc. - Special Call - Seeking Alpha
- 4 months ago - Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds - GlobeNewsWire
- 4 months ago - Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile - GlobeNewsWire
- 6 months ago - Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results - GlobeNewsWire